LSV Asset Management Acquires 270,834 Shares of Indivior PLC $INDV

LSV Asset Management boosted its holdings in shares of Indivior PLC (NASDAQ:INDV) by 1,334.2% during the 4th quarter, Holdings Channel reports. The firm owned 291,134 shares of the company’s stock after buying an additional 270,834 shares during the period. LSV Asset Management’s holdings in Indivior were worth $10,446,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the stock. PNC Financial Services Group Inc. grew its stake in Indivior by 2,930.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,485 shares of the company’s stock valued at $269,000 after acquiring an additional 7,238 shares in the last quarter. ProShare Advisors LLC boosted its holdings in shares of Indivior by 15.7% in the 4th quarter. ProShare Advisors LLC now owns 29,139 shares of the company’s stock worth $1,046,000 after purchasing an additional 3,949 shares during the period. Oregon Public Employees Retirement Fund purchased a new position in shares of Indivior in the 4th quarter worth approximately $1,026,000. Independent Advisor Alliance bought a new stake in shares of Indivior during the 4th quarter worth approximately $791,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its stake in shares of Indivior by 3.4% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock worth $761,000 after acquiring an additional 700 shares during the last quarter. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Stock Performance

INDV opened at $37.53 on Tuesday. The stock has a fifty day moving average price of $33.52 and a 200-day moving average price of $33.78. Indivior PLC has a 12 month low of $11.08 and a 12 month high of $41.00. The firm has a market cap of $4.58 billion, a price-to-earnings ratio of 19.25 and a beta of 0.90.

Indivior (NASDAQ:INDV) last announced its earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%.The company had revenue of $317.00 million for the quarter. On average, equities research analysts forecast that Indivior PLC will post 3.35 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on INDV. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 16th. Weiss Ratings lowered Indivior from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Indivior currently has a consensus rating of “Buy” and a consensus target price of $39.33.

Insider Transactions at Indivior

In other Indivior news, Director Stuart A. Kingsley bought 940 shares of Indivior stock in a transaction that occurred on Friday, March 6th. The shares were bought at an average cost of $31.86 per share, with a total value of $29,948.40. Following the transaction, the director directly owned 5,582 shares of the company’s stock, valued at approximately $177,842.52. This represents a 20.25% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.74% of the stock is owned by corporate insiders.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.